Service technology platform for discovery of antibody fragments with therapeutic and diagnostic potential
Generating new and active biological molecules is not possible without appropriate technologies. Pure Biologics has developed two platforms enabling fast and efficient identification of antibodies and aptamers. Pure Biologics currently holds the rights to the PureSelect2 platform.
PureSelect2 is our platform for obtaining antibodies in vitro using phage display technology. It is the successor and more advanced version of our previous selection platform – PureSelect. PureSelect2 overcomes previous limitations, thereby increasing the efficiency and versatility of the selection process, and enabling the discovery of antibodies against almost any molecular target.